Skip to main content
ACG 2025 Annual Meeting Main banner
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Award Winner
ACG Newsworthy Abstract
ACG Newsworthy Abstract
Registration Required
Registration Required
No CME
No CME
On-Demand Video
On-Demand Video
Livestream
Livestream

Sunday Poster Session

Category: Liver

P1636 - Prognostic Value of High-Sensitivity CRP Metabolic Associated Steatotic Liver Disease: A Propensity-Matched Analysis Using the TriNetX Research Network

Sunday, October 26, 2025
3:30 PM - 7:00 PM MT
Location: Exhibit Hall
Meklit Hunde, MD1, Ekow Essien, MD1, Abena Agyekum, MD2
1Aurora Healthcare, Milwaukee, WI; 2SUNY Downstate Health Sciences University, Brooklyn, NY

Introduction: Metabolic associated steatotic liver disease (MASLD) is associated with increased cardiovascular risk and mortality, but the prognostic value of high-sensitivity C-reactive protein (hsCRP) in this population remains incompletely characterized. This study aimed to compare clinical outcomes between MASLD patients with elevated versus normal hsCRP levels.

Methods: We performed a retrospective cohort study using the TriNetX Research Network, a global federated health research platform providing access to electronic medical records across 146 healthcare organizations. Patients with MASLD (ICD-10 code K76.0) were stratified by hsCRP levels: elevated (≥3.10 mg/L) versus normal (≤3.00 mg/L). After propensity score matching for baseline demographics and comorbidities, cohorts of 39,419 patients each were analyzed. The primary outcome was all-cause mortality. Secondary outcomes included heart failure, chronic kidney disease, atrial fibrillation, cerebrovascular disease, pulmonary embolism, acute myocardial infarction, pulmonary hypertension, coronary artery disease, diabetes mellitus, liver cirrhosis, and hypertension. Outcomes were analyzed using risk analysis and Kaplan-Meier survival analysis over a five-year follow-up period.

Results: In this propensity-matched cohort study, MASLD patients with elevated hsCRP demonstrated significantly higher all-cause mortality compared to those with normal hsCRP (11.0% vs 4.0%; HR 2.925, 95% CI 2.761-3.098; p< 0.001). Elevated hsCRP was also associated with increased incidence of heart failure (7.1% vs 4.4%; HR 1.718, 95% CI 1.612-1.831; p< 0.001), chronic kidney disease (7.9% vs 5.7%; HR 1.488, 95% CI 1.404-1.578; p< 0.001), atrial fibrillation and flutter (4.7% vs 3.3%; HR 1.531, 95% CI 1.421-1.649; p< 0.001), acute myocardial infarction (3.9% vs 2.2%; HR 1.868, 95% CI 1.715-2.035; p< 0.001), liver cirrhosis (4.4% vs 3.3%; HR 1.431, 95% CI 1.327-1.542; p< 0.001), and diabetes mellitus (12.6% vs 8.8%; HR 1.577, 95% CI 1.494-1.665; p< 0.001).

Discussion: In MASLD patients, elevated hsCRP levels are associated with significantly increased all-cause mortality and multiple adverse cardiovascular and metabolic outcomes. These findings suggest that hsCRP may serve as an important prognostic biomarker for risk stratification in MASLD patients and should be considered in clinical management algorithms.

Disclosures:
Meklit Hunde indicated no relevant financial relationships.
Ekow Essien indicated no relevant financial relationships.
Abena Agyekum indicated no relevant financial relationships.

Meklit Hunde, MD1, Ekow Essien, MD1, Abena Agyekum, MD2. P1636 - Prognostic Value of High-Sensitivity CRP Metabolic Associated Steatotic Liver Disease: A Propensity-Matched Analysis Using the TriNetX Research Network, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.